ReviewAdvances in experimental medicine and biology2020
Application of iPSC to Modelling of Respiratory Diseases.
Review in Advances in experimental medicine and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Genetic associations in sepsis and ARDS.Frontiers in pharmacology · 2026Review
- Organotypic Airway Models Derived from Primary Human Nasal Epithelial Cells.Current allergy and asthma reports · 2025Review
- Distal lung organoids derived from adult stem cells as novel tools in deciphering mechanisms of lung regeneration, infection, and cancer.Stem cells translational medicine · 2025Review
- Airway Organoid Models as Pivotal Tools for Unraveling Molecular Mechanisms and Therapeutic Targets in Respiratory Diseases: A Literature Review.Therapeutics and clinical risk management · 2025Review
- CRISPR-Cas9 Genome Editing Allows Generation of the Mouse Lung in a Rat.American journal of respiratory and critical care medicine · 2024Article
- Advanced models for respiratory disease and drug studies.Medicinal research reviews · 2023Review
- Modeling of Respiratory Diseases Evolving with Fibrosis from Organoids Derived from Human Pluripotent Stem Cells.International journal of molecular sciences · 2023Review
- Basic Science Perspective on Engineering and Modeling the Large Airways.Advances in experimental medicine and biology · 2023Article
- Development and characterization of ferretFrontiers in medicine · 2023Article
- Application of Precision-Cut Lung Slices as an In Vitro Model for Research of Inflammatory Respiratory Diseases.Bioengineering (Basel, Switzerland) · 2022Review
- Enhancement of airway epithelial cell differentiation by pulmonary endothelial cell co-culture.Stem cell research · 2022Article
- Identification of MAEL as a promoter for the drug resistance model of iPSCs derived from T-ALL.Cancer medicine · 2022Article
- Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies.The CRISPR journal · 2022Review
- Organoid technology and applications in lung diseases: Models, mechanism research and therapy opportunities.Frontiers in bioengineering and biotechnology · 2022Review
- Long-term differentiating primary human airway epithelial cell cultures: how far are we?Cell communication and signaling : CCS · 2021Review
- Article
- Stem cells and lung regeneration.American journal of physiology. Cell physiology · 2020Review
- A Systematic Review on Traditional Uses, Sources, Phytochemistry, Pharmacology, Pharmacokinetics, and Toxicity of Fritillariae Cirrhosae Bulbus.Evidence-based complementary and alternative medicine : eCAM · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
Abstract
Respiratory disease is one of the leading causes of morbidity and mortality world-wide with an increasing incidence as the aged population prevails. Many lung diseases are treated for symptomatic relief, with no cure available, indicating a critical need for novel therapeutic strategies. Such advances are hampered by a lack of understanding of how human lung pathologies initiate and progress. Research on human lung disease relies on the isolation of primary cells from explanted lungs or the use of immortalized cells, both are limited in their capacity to represent the genomic and phenotypic variability among the population. In an era where we are progressing toward precision medicine the use of patient specific induced pluripotent cells (iPSC) to generate models, where sufficient primary cells and tissues are scarce, has increased our capacity to understand human lung pathophysiology. Directed differentiation of iPSC toward lung presented the initial challenge to overcome in generating iPSC-derived lung epithelial cells. Since then major advances have been made in defining protocols to specify and isolate specific lung lineages, with the generation of airway spheroids and multi cellular organoids now possible. This technological advance has opened up our capacity for human lung research and prospects for autologous cell therapy. This chapter will focus on the application of iPSC to studying human lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.